Key result
In patients with fulminant myocarditis requiring VA-ECMO, LV unloading with Impella significantly reduced the 30-day incidence of all-cause mortality or exVAD implantation compared to IABP (8% vs 53%).
Why the study?
Clinical differences between IABP and a microaxial flow pump (Impella) for LV unloading in patients with fulminant myocarditis supported with VA-ECMO remain unclear.
Does Impella improve short-term clinical outcomes compared to IABP in patients with fulminant myocarditis supported by VA-ECMO?
Cohort (n=27)
No
Does Impella improve short-term clinical outcomes compared to IABP in patients with fulminant myocarditis supported by VA-ECMO?
In patients with fulminant myocarditis requiring VA-ECMO, left ventricular unloading with Impella was associated with improved 30-day event-free survival compared to IABP, though with a higher incidence of hemolysis.
May support Impella for LV unloading in VA-ECMO myocarditis; hypothesis-generating and requires randomized confirmation.
Background: The clinical differences between intra-aortic balloon pumping (IABP) and a microaxial flow pump (Impella) for left ventricular (LV) unloading in patients with fulminant myocarditis (FM) supported with venoarterial extracorporeal membrane oxygenation (VA-ECMO) remain unclear. Methods and Results: In this single-center, retrospective cohort study, we analyzed 27 consecutive patients with lymphocytic FM who received VA-ECMO support. Patients were stratified by the LV unloading device that was used: IABP (n=15); or Impella (n=12). The primary endpoint was a composite of all-cause mortality or implantation of an extracorporeal ventricular assist device (exVAD) within 30 days of VA-ECMO initiation. Temporal changes in laboratory and hemodynamic parameters during the first 7 days of support were also assessed. Baseline characteristics, including LV ejection fraction (IABP 16% vs. Impella 18%; P=0.814) and QRS duration (139 vs. 105 ms; P=0.805), were comparable between groups. Nine patients met the primary endpoint (mortality [n=7]; exVAD implantation [n=2]). Kaplan-Meier analysis revealed a significantly lower incidence of the primary endpoint in the Impella group (log-rank P=0.018). The Impella group also showed a significantly greater improvement in cardiac power output (group×time interaction, P=0.040). Hemolysis, elevated total bilirubin, and increased serum creatinine were more pronounced in the Impella group. Conclusions: In patients with FM requiring VA-ECMO, LV unloading with Impella was associated with improved short-term clinical outcomes compared with IABP.
No takes yet. Share an insight, caveat, or question.
Iikura et al. (2026) conducted a cohort in Fulminant myocarditis supported with VA-ECMO (n=27). Impella (microaxial flow pump) vs. Intra-aortic balloon pump (IABP) was evaluated on Composite of all-cause mortality or implantation of an extracorporeal ventricular assist device (exVAD) within 30 days of VA-ECMO initiation (p=0.018). In patients with fulminant myocarditis requiring VA-ECMO, LV unloading with Impella significantly reduced the 30-day incidence of all-cause mortality or exVAD implantation compared to IABP (8% vs 53%).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: